Long-Term Clinical Outcomes Of Subjects Enrolled In The RxSight Light Adjustable Lens (LAL) And Light Delivery Device (LDD) New Enrollment Study

NCT07347379 · tracked via the Priya Life Science USA tracker

Sponsor

RxSight, Inc.

Phase

Observational

Started

2025-11-13

Last updated

2026-08-12

Condition(s) studied

Aphakia Cataract

Investigational drug(s) / intervention(s)

Light Adjustable lens (LAL) and Light Delivery Device (LDD)

Light Adjustable lens (LAL) and Light Delivery Device (LDD): Experimental treatment group received Light adjustable lens with Light delivery Device treatments

Study summary

This is an observational, follow up study of subjects previously enrolled in the "RxSight Light Adjustable Lens (LAL) and Light Delivery Device (LDD) New Enrollment Study". The primary objective of this study is to collect long-term safety and effectiveness data on RxSight LAL in subjects previously implanted in the "RxSight Light Adjustable Lens (LAL) and Light Delivery Device (LDD) New Enrollment Study".

Eligibility

Sex

ALL

Min age

—

Max age

—

Healthy volunteers

Inclusion Criteria: * Subject and study eye with prior participation in the CSP-029 study and implanted with the LAL. Exclusion Criteria: * Subjects with serious co-morbid conditions that in the judgment of the investigator makes inclusion in the study not in the best interest of the subject.

Primary outcome measure(s)

Mean absolute manifest refraction spherical equivalent (|MRSE|) at the Long-Term follow up visit — Up to 55 months
Mean manifest cylinder at the Long-Term follow up visit — Up to 55 months

Trial sites (1)

Facility	City	Region	Status
Focal Point Vision	San Antonio	Texas

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07347379 on ClinicalTrials.gov ↗ ← All trials in the USA